Cargando…
Sodium-Glucose Co-Transporter 2 Inhibitors Use Improves the Satisfaction With Anti-diabetic Agent Treatment: A Questionnaire-based Propensity Score-matched Study
Background: Specific safety issues with sodium-glucose co-transporter-2 (SGLT2) inhibitors such as infection, fractures, worsening of renal function and euglycemic ketoacidosis have been raised. Concerns about adverse events might limit the use of this drug class. The satisfaction with SGLT2 inhibit...
Autores principales: | Shi, Fang-Hong, Yue, Jiang, Jiang, Yi-Hong, Yang, Ming-Lan, Gu, Zhi-Chun, Ma, Jing, Li, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844021/ https://www.ncbi.nlm.nih.gov/pubmed/35177981 http://dx.doi.org/10.3389/fphar.2021.787704 |
Ejemplares similares
-
Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
por: Armour, Sarah L., et al.
Publicado: (2022) -
Appraisal of Non-Cardiovascular Safety for Sodium–Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials
por: Shi, Fang-Hong, et al.
Publicado: (2019) -
Intervention by clinical pharmacists can improve blood glucose fluctuation in patients with diabetes and acute myocardial infarction: A propensity score‐matched analysis
por: Shi, Fang‐Hong, et al.
Publicado: (2021) -
Effects of public reporting of prescription indicators on patient choices: evidence from propensity scores matching
por: Chen, Manli, et al.
Publicado: (2023) -
Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)